← Back to Search

Virus Vaccine

Inactivated Influenza Vaccine for Influenza (FLU-LN Trial)

Phase 4
Waitlist Available
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Body mass index (BMI) 20-35 kg/m2
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 7 after vaccination
Awards & highlights

FLU-LN Trial Summary

This trial is testing how well the flu vaccine works in people with HIV.

Eligible Conditions
  • Influenza

FLU-LN Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Your body weight is within a healthy range based on your height.

FLU-LN Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 7 after vaccination
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 7 after vaccination for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
HAI titer

FLU-LN Trial Design

1Treatment groups
Experimental Treatment
Group I: Study PhaseExperimental Treatment1 Intervention
Participants will be given the current year's a quadrivalent inactivated influenza vaccine (IIV)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Quadrivalent inactivated influenza vaccine (IIV)
2019
Completed Phase 1
~10

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,374 Previous Clinical Trials
17,332,927 Total Patients Enrolled
National Institutes of Health (NIH)NIH
2,679 Previous Clinical Trials
6,910,682 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,261 Previous Clinical Trials
5,483,006 Total Patients Enrolled

Media Library

Quadrivalent inactivated influenza vaccine (IIV) (Virus Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT03898973 — Phase 4
Influenza Research Study Groups: Study Phase
Influenza Clinical Trial 2023: Quadrivalent inactivated influenza vaccine (IIV) Highlights & Side Effects. Trial Name: NCT03898973 — Phase 4
Quadrivalent inactivated influenza vaccine (IIV) (Virus Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03898973 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this particular therapy received governmental authorization?

"The safety of this therapeutic intervention is rated a 3 on our 1-3 scale due to it being in its fourth phase, which indicates that the treatment has already been approved."

Answered by AI

What is the sample size of this research project?

"Affirmative, the clinicaltrials.gov portal indicates that recruitment for this medical trial is ongoing. It was first listed on April 11th 2019 and modified most recently on May 3rd 2022. The investigation aims to include 50 individuals from a single research centre."

Answered by AI

Is the enrollment process for this experiment currently open?

"Yes, according to clinicaltrials.gov, this biomedical research is currently enrolling 50 individuals from one centre; the trial was originally posted on April 11th 2019 and recently updated on May 3rd 2022."

Answered by AI

What are the requirements for participating in this trial?

"Eligibility for the experiment necessitates that patients have contracted an influenza virus and are within the ages of 20 to 75. The study is looking to recruit around 50 individuals."

Answered by AI

Is there precedent for this particular therapeutic intervention?

"Currently, 14 different clinical trials are running to investigate this particular treatment. One of these is in its terminal stage - Phase 3 - and the majority are situated at Stanford University, California; though 15 sites in total offer studies for it."

Answered by AI

Is the eligibility criterion for this medical trial inclusive of individuals younger than forty?

"In line with the study's requirements, potential participants must be between 20 and 75 years of age."

Answered by AI

Does this trial represent a novel approach to treatment?

"Currently, 14 active trials are ongoing across 10 cities and 3 countries for this medication. Initially launched by Pharmacyclics LLC in 2016, the phase 2 clinical trial enrolled 42 participants to meet its drug approval criteria. Subsequently, an additional 143 studies have been conducted over the last 5 years."

Answered by AI
~0 spots leftby Mar 2025